Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,758 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study.
de Jong LAW, Elekonawo FMK, Lambert M, de Gooyer JM, Verheul HMW, Burger DM, de Wilt JHW, Chatelut E, Ter Heine R, de Reuver PR, Bremers AJA, van Erp NP. de Jong LAW, et al. Among authors: lambert m. Cancer Chemother Pharmacol. 2020 Jul;86(1):141-150. doi: 10.1007/s00280-020-04107-y. Epub 2020 Jun 27. Cancer Chemother Pharmacol. 2020. PMID: 32594200 Free PMC article. Clinical Trial.
Correction to: Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin‑based HIPEC: results of the GUTOX study.
de Jong LAW, Elekonawo FMK, Lambert M, de Gooyer JM, Verheul HMW, Burger DM, de Wilt JHW, Chatelut E, Ter Heine R, de Reuver PR, Bremers AJA, van Erp NP. de Jong LAW, et al. Among authors: lambert m. Cancer Chemother Pharmacol. 2022 Aug;90(2):189-190. doi: 10.1007/s00280-022-04450-2. Cancer Chemother Pharmacol. 2022. PMID: 35731259 Free PMC article. No abstract available.
Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide.
Valentin T, Lambert M, Chaltiel L, Allal B, Mseddi M, Yakoubi M, Chevreau C, Toulmonde M, Firmin N, Filleron T, Chatelut E. Valentin T, et al. Among authors: lambert m. Eur J Pharm Sci. 2023 Jun 1;185:106420. doi: 10.1016/j.ejps.2023.106420. Epub 2023 Mar 5. Eur J Pharm Sci. 2023. PMID: 36882147 Free article.
[Rapid Assessment of Future Pandemic Effects in Individuals with Severe Mental Illness: Can Ongoing Population-Representative Cohorts Contribute?].
Wittmann FG, Luppa M, Höhn A, Wege N, Ascone L, Lohse L, Hurlemann R, Meisenzahl E, Lambert M, Bajbouj M, von Lilienfeld-Toal M, Riedel-Heller SG. Wittmann FG, et al. Among authors: lambert m. Psychiatr Prax. 2025 Jan 9. doi: 10.1055/a-2500-2379. Online ahead of print. Psychiatr Prax. 2025. PMID: 39788527 German.
International Consensus in Aiming to Define "Refractory ITP".
O'Farrell C, Grimes AB, Nakano TA, Klaassen RJ, Lambert MP, Neunert CE, Rothman JA, Shimano KA, Grace RF. O'Farrell C, et al. Among authors: lambert mp. Blood Adv. 2025 Jan 9:bloodadvances.2024015219. doi: 10.1182/bloodadvances.2024015219. Online ahead of print. Blood Adv. 2025. PMID: 39787601 No abstract available.
A year in review: innovations and insights from 2024.
Lambert M, Dankel M. Lambert M, et al. JBI Evid Synth. 2025 Jan 1;23(1):1-3. doi: 10.11124/JBIES-24-00509. Epub 2025 Jan 2. JBI Evid Synth. 2025. PMID: 39774075 No abstract available.
2,758 results